70. Spinal stenosis Clinical trials / Disease details
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05630404 (ClinicalTrials.gov) | November 28, 2022 | 1/11/2022 | Efficacy of Surgical Injection Lumbar Erector Spinae Plane Block | Efficacy of Surgical Injection Lumbar Erector Spinae Plane Block for Pain Management Following Lumbar Spinal Fusion Surgery | Lumbar Spine Instability;Lumbar Spinal Stenosis;Lumbar Spine Degeneration | Drug: Surgical ESPB;Drug: US guided ESPB | Bursa City Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 90 | N/A | Turkey |
| 2 | NCT05345249 (ClinicalTrials.gov) | June 1, 2022 | 28/3/2022 | Erector Spinae Plane Block as Pain Management After Lumbar Fusion Surgery | Erector Spinae Plane Block for Reduction of Early Postoperative Pain Scores and Opioid Use in Lumbar Spinal Fusion Surgery, a Prospective Double-blinded Randomized Placebo-controlled Trial | Spondylolisthesis;Lumbar Disc Herniation;Lumbar Spinal Stenosis;Lumbar Disc Disease;Lumbar Spondylolisthesis;Lumbar Spondylosis;Lumbar Spine Disease;Lumbar Radiculitis;Spinal Fusion;Fusion of Spine;Spondylosis Lumbosacral Region | Drug: Ropivacaine Hydrochloride Injection;Drug: Sodium chloride | Maaike Fenten | Radboud University Medical Center | Recruiting | 18 Years | N/A | All | 76 | Phase 4 | Netherlands |
| 3 | ChiCTR2100053054 | 2021-11-09 | 2021-11-10 | Desomumab and lumbar spinal stenosis | Evaluation of bone mineral density and function at 1 year after lumbar spinal stenosis and fusion with desomumab: a parallel double-blind randomized controlled clinical trial | Lumber disease | Group A:Denosumab;Group B:Placebo; | The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology | NULL | Recruiting | 40 | 90 | Both | Group A:40;Group B:40; | Phase 4 | China |
| 4 | NCT04483297 (ClinicalTrials.gov) | November 18, 2020 | 14/7/2020 | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery | Degenerative Spondylolisthesis;Spinal Stenosis | Drug: AK1320 MS;Other: Control | Asahi Kasei Pharma Corporation | Emergent Clinical Consulting, LLC | Active, not recruiting | 22 Years | 80 Years | All | 40 | Phase 1 | Canada |
| 5 | NCT04042948 (ClinicalTrials.gov) | June 24, 2019 | 13/7/2019 | Clinical Effect of Preventive Use of Tylenol on Fever After Removal of Drainage Tube in Lumbar Fusion Surgery | Randomized Controlled Study of Fever Probability, Risk Factors and Preventive Use of Non-steroidal Anti-inflammatory Drugs on Fever After Removal of Drainage Tube After Lumbar Fusion | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Radiculopathy | Drug: Tylenol | Peking University Third Hospital | NULL | Completed | 18 Years | N/A | All | 183 | N/A | China |
| 6 | NCT04007094 (ClinicalTrials.gov) | February 12, 2019 | 24/4/2019 | Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery | A Prospective, Single Arm Study of Patients Undergoing Posterolateral Lumbar Fusion (Without Interbody) Supplemented With ViviGen Cellular Bone Matrix | Degenerative Disc Disease;Spinal Stenosis;Spondylosis;Spondylolisthesis | Drug: ViviGen Cellular Bone Matrix | Ohio State University | DePuy Synthes | Recruiting | 18 Years | N/A | All | 50 | Phase 4 | United States |
| 7 | NCT03745040 (ClinicalTrials.gov) | January 26, 2019 | 5/11/2018 | Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion | Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Disc Disease;Lumbar Spondylolisthesis | Drug: Liposomal bupivacaine | Allina Health System | Twin Cities Spine Center | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
| 8 | NCT03883022 (ClinicalTrials.gov) | September 3, 2018 | 10/3/2019 | Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery | Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery | Spinal Fusion;Spinal Stenosis;Spondylolisthesis | Drug: with U-VANCO (vancomycin hydrochloride);Drug: without U-VANCO (vancomycin hydrochloride) | Taipei Veterans General Hospital, Taiwan | NULL | Recruiting | 20 Years | N/A | All | 400 | N/A | Taiwan |
| 9 | ChiCTR1800016968 | 2018-07-15 | 2018-07-05 | A prospective study on the effect of different antiosteoporosis drugs on patients after lumbar fusion surgery | A prospective study on the effect of different antiosteoporosis drugs on patients after lumbar fusion surgery | Osteoporosis with lumbar spinal stenosis | C:Lumbar Fusion Surgery+Basic anti-osteoporosis drugs;A:Lumbar Fusion Surgery+MenatetrenoneSoft Capsules;B:Lumbar Fusion Surgery+Teriparatide acetate; | Qilu Hospital of Shandong University | NULL | Recruiting | 20 | 80 | Both | C:40;A:40;B:40; | China | |
| 10 | EUCTR2016-002887-14-FI (EUCTR) | 31/10/2016 | 14/10/2016 | Dose-response of ketamine in patient controlled analgesia in orthopaedic surgery patients | Dose response study of Patient Controlled Analgesia (PCA) of S-ketamine in orthopaedic spine surgery patients - DoseRespKeta | Patients who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 19.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Ketanest-S INN or Proposed INN: KETAMINE Trade Name: Oxycodone Orion INN or Proposed INN: OXYCODONE | University of Turku | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 1;Phase 4 | Finland | ||
| 11 | NCT02700451 (ClinicalTrials.gov) | March 2016 | 18/2/2016 | Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes | A Randomized Controlled Trial of Post-operative Acetaminophen Versus Nonsteroidal Anti-Inflammatory Drug (NSAID) Use on Lumbar Spinal Fusion Outcomes | Lumbar Osteoarthritis;Spondylosis;Lumbar Disc Disease;Spinal Stenosis | Drug: Ketorolac;Drug: Acetaminophen;Drug: Placebo | Hospital for Special Surgery, New York | NULL | Active, not recruiting | 18 Years | 75 Years | All | 300 | N/A | United States |
| 12 | EUCTR2014-003252-31-FI (EUCTR) | 15/05/2015 | 22/04/2015 | Dose-response of dexmedetomidine in patient controlled analgesia in orthopaedic surgery patients | Dose response study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in orthopaedic spine surgery patients - DoserespDex_2.0 | Patients, who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation MedDRA version: 17.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Dexdor INN or Proposed INN: deksmedetomidiini Other descriptive name: DEXMEDETOMIDINE HYDROCHLORIDE Trade Name: Oxanest INN or Proposed INN: oksikodoni Other descriptive name: OXYCODONE HYDROCHLORIDE | University of Turku | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 13 | NCT02070484 (ClinicalTrials.gov) | February 2014 | 21/2/2014 | Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease | Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease | Lumbar Degenerative Disc Disease;Spinal Stenosis;Spondylolisthesis;Spondylosis;Intervertebral Disk Displacement;Intervertebral Disk Degeneration;Spinal Diseases;Bone Diseases;Musculoskeletal Diseases;Spondylolysis | Biological: NuCel;Biological: Demineralized Bone Matrix | OhioHealth | NuTech Medical, Inc | Terminated | 18 Years | 75 Years | All | 6 | N/A | United States |
| 14 | NCT02090244 (ClinicalTrials.gov) | August 2012 | 16/3/2014 | Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans? | Förbättrar PTH Postero-lateral fusionsläkning Vid Ryggkirurgi? | Spinal Stenosis | Drug: Teriparatide | University Hospital, Linkoeping | Medical Research Council of Southeast Sweden | Completed | N/A | N/A | All | 34 | Phase 4 | Sweden |
| 15 | EUCTR2011-006152-36-DK (EUCTR) | 10/05/2012 | 10/05/2012 | Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing? | Postoperative treatment with parathyroidea hormone Forteo® inpatients undergoing posterolateral spinal fusion surgery. A prospektiveand a randomized double-blinded, placebo-controlled study - PTH-U-DESE-STUDY | Spinal stenosis MedDRA version: 14.1;Level: LLT;Classification code 10041597;Term: Spinal stenosis of lumbar region;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Forteo Product Name: Forsteo Product Code: 0002-8971 INN or Proposed INN: teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) Other descriptive name: rhPTH (1-34) | Middelfart Rygsektor | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Denmark | ||
| 16 | EUCTR2011-002917-12-SE (EUCTR) | 06/12/2011 | 27/09/2011 | Does parathyroid hormone enhance healing after spinal fusion? | Does PTH enhance healing after spinal fusion? - PTH spinal stenosis | Decompression and fusion due to spinal stenosis in men and postmenopausal women. In this study we want to examine if Forsteo (teriparatide) improves bone healing (jugded by blinded investigators) and if this improves the function and decreases the pain at 7 weeks and 6 months.;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] | Trade Name: Forsteo | Department of Orthopaedics IKE | Department of Orthopaedics IKE | Not Recruiting | Female: yes Male: yes | 100 | Phase 4 | Sweden | ||
| 17 | NCT01377623 (ClinicalTrials.gov) | September 2010 | 3/1/2011 | Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion | Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion | Spinal Stenosis;Inflammation | Drug: Dexmedetomidine group;Drug: Placebo group | New York University School of Medicine | Hospira, now a wholly owned subsidiary of Pfizer | Terminated | 18 Years | N/A | All | 66 | N/A | United States |
| 18 | NCT01106417 (ClinicalTrials.gov) | June 2010 | 16/4/2010 | Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion | Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation | Cervical Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Device: MasterGraft Granules | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 12 | Phase 1/Phase 2 | Australia |
| 19 | NCT01097486 (ClinicalTrials.gov) | June 2010 | 30/3/2010 | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy | Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation | Cervical Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Procedure: Allograft | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
| 20 | NCT00996073 (ClinicalTrials.gov) | September 2009 | 9/10/2009 | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion | A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation | Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Biological: Lumbar Interbody Fusion with Autograft;Biological: Lumbar Interbody Fusion with NeoFuse | Mesoblast, Ltd. | NULL | Completed | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
| 21 | NCT00808665 (ClinicalTrials.gov) | June 2009 | 15/12/2008 | Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion | Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study | Spinal Fusion Acquired;Spinal Stenosis;Lesions of Lumbosacral Intervertebral Disc;Spinal Diseases | Drug: Dexmedetomidine;Drug: 0.9% Saline | Vanderbilt University Medical Center | NULL | Completed | 18 Years | 85 Years | All | 68 | Phase 4 | United States |
| 22 | NCT00810212 (ClinicalTrials.gov) | November 2008 | 17/12/2008 | Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion | A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With Mastergraft Granules in Subjects Undergoing Posterolateral Lumbar Fusion With Instrumentation | Degenerative Disc Disease;Degenerative Spondylolisthesis;Spinal Stenosis | Procedure: PLF with autograft;Biological: PLF with NeoFuse | Mesoblast, Ltd. | NULL | Withdrawn | 18 Years | 70 Years | All | 0 | Phase 1/Phase 2 | United States |
| 23 | NCT00549913 (ClinicalTrials.gov) | October 2007 | 24/10/2007 | Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) | A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation. | Degenerative Disc Disease;Spondylolisthesis;Spinal Stenosis | Biological: NeoFuse;Procedure: posterolateral spinal fusion with instrumentation | Mesoblast, Ltd. | NULL | Completed | 18 Years | N/A | All | 6 | Phase 1/Phase 2 | United States |